192 related articles for article (PubMed ID: 38400610)
1. Autoimmune Movement Disorders Complicating Treatment with Immune Checkpoint Inhibitors.
Dinoto A; Trentinaglia M; Carta S; Mantovani E; Ferrari S; Tamburin S; Tinazzi M; Mariotto S
Mov Disord Clin Pract; 2024 May; 11(5):543-549. PubMed ID: 38400610
[TBL] [Abstract][Full Text] [Related]
2. Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management.
Farina A; Villagrán-García M; Honnorat J
Rev Neurol (Paris); 2023 Jun; 179(5):506-515. PubMed ID: 36934022
[TBL] [Abstract][Full Text] [Related]
3. Cerebellar involvement associated with immune checkpoint inhibitors: A systematic review.
Dinoto A; Mantovani E; Ferrari S; Mariotto S; Tamburin S
Eur J Neurol; 2023 Mar; 30(3):774-781. PubMed ID: 36325694
[TBL] [Abstract][Full Text] [Related]
4. Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea.
Hyun JW; Kim KH; Kim SH; Kim HJ
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5583-5589. PubMed ID: 36495331
[TBL] [Abstract][Full Text] [Related]
5. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review.
Velasco R; Villagrán M; Jové M; Simó M; Vilariño N; Alemany M; Palmero R; Martínez-Villacampa MM; Nadal E; Bruna J
JAMA Neurol; 2021 Jul; 78(7):864-873. PubMed ID: 33720308
[TBL] [Abstract][Full Text] [Related]
6. Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer.
Zhou L; Wei X
Front Immunol; 2021; 12():701951. PubMed ID: 34504488
[TBL] [Abstract][Full Text] [Related]
7. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
Bhatlapenumarthi V; Patwari A; Harb AJ
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
[TBL] [Abstract][Full Text] [Related]
8. Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies.
Seki M; Kitano S; Suzuki S
Cancer Immunol Immunother; 2022 Apr; 71(4):769-775. PubMed ID: 34515815
[TBL] [Abstract][Full Text] [Related]
9. Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases.
Pizuorno Machado A; Shatila M; Liu C; Wang J; Altan M; Zhang HC; Thomas A; Wang Y
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6341-6350. PubMed ID: 36752908
[TBL] [Abstract][Full Text] [Related]
10. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
Yang F; Shay C; Abousaud M; Tang C; Li Y; Qin Z; Saba NF; Teng Y
J Exp Clin Cancer Res; 2023 Jan; 42(1):4. PubMed ID: 36600271
[TBL] [Abstract][Full Text] [Related]
11. Safety of immune checkpoint inhibitors in patients with preexisting autoimmune disorders.
Kumar R; Chan A; Bandikatla S; Ranjan S; Ngo P
Curr Probl Cancer; 2022 Aug; 46(4):100864. PubMed ID: 35671576
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis.
Cai Q; Huo GW; Zhu FY; Yue P; Yuan DQ; Chen P
Hum Vaccin Immunother; 2022 Dec; 18(7):2145102. PubMed ID: 36471629
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitors in Patients with Pre-existing Neurologic Autoimmune Disorders.
Aoun R; Gratch D; Kaminetzky D; Kister I
Curr Neurol Neurosci Rep; 2023 Nov; 23(11):735-750. PubMed ID: 37870664
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer.
Berti A; Bortolotti R; Dipasquale M; Kinspergher S; Prokop L; Grandi G; Inchiostro S; Paolazzi G; Caffo O; Veccia A
Crit Rev Oncol Hematol; 2021 Jun; 162():103351. PubMed ID: 33989769
[TBL] [Abstract][Full Text] [Related]
15. PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease.
Kocheise L; Piseddu I; Vonderlin J; Tjwa ET; Buescher G; Meunier L; Goeggelmann P; Fianchi F; Dumortier J; Riveiro Barciela M; Gevers TJG; Terziroli Beretta-Piccoli B; Londoño MC; Frankova S; Roesner T; Joerg V; Schmidt C; Glaser F; Sutter JP; Fründt TW; Lohse AW; Huber S; von Felden J; Sebode M; Schulze K
Front Immunol; 2023; 14():1326078. PubMed ID: 38268921
[TBL] [Abstract][Full Text] [Related]
16. Pre-existing Autoimmune Diseases and Immune Checkpoint Inhibitors for Cancer Treatment: Considerations About Initiation, Flares, Immune-Related Adverse Events, and Cancer Progression.
Sparks JA
Rheum Dis Clin North Am; 2024 May; 50(2):147-159. PubMed ID: 38670718
[TBL] [Abstract][Full Text] [Related]
17. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
18. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
[TBL] [Abstract][Full Text] [Related]
19. Neurologic manifestations of autoimmunity with immune checkpoint inhibitors.
McCombe JA; Sechi E; Zekeridou A
Handb Clin Neurol; 2024; 200():449-465. PubMed ID: 38494296
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
Front Immunol; 2021; 12():730320. PubMed ID: 34646270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
